HC Wainwright Has Strong Estimate for BioNTech Q1 Earnings

BioNTech SE (NASDAQ:BNTX) – Research analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of BioNTech in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst R. Burns now expects that the company will earn ($2.34) per share for the quarter, up from their prior estimate of ($3.42). HC Wainwright has a “Buy” rating and a $145.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2025 earnings at ($2.52) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at $0.58 EPS and FY2025 earnings at ($5.51) EPS.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.90 EPS.

Several other research analysts have also commented on the company. Citigroup initiated coverage on BioNTech in a report on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective for the company. Morgan Stanley cut their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Wells Fargo & Company initiated coverage on BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and an average target price of $143.44.

BioNTech Stock Performance

NASDAQ BNTX opened at $88.05 on Friday. The company’s 50 day simple moving average is $108.81 and its two-hundred day simple moving average is $112.80. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The stock has a market capitalization of $21.13 billion, a PE ratio of -41.93 and a beta of 1.07.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Charles Schwab Investment Management Inc. increased its position in shares of BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares during the period. SG Americas Securities LLC increased its holdings in BioNTech by 412.3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after purchasing an additional 33,375 shares during the period. Mirabaud & Cie SA bought a new position in BioNTech during the 4th quarter valued at approximately $684,000. Redmile Group LLC bought a new position in BioNTech during the 3rd quarter valued at approximately $18,345,000. Finally, Bank of New York Mellon Corp lifted its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after buying an additional 150 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.